Cabaletta Bio (CABA) Competitors $1.63 -0.06 (-3.55%) Closing price 04:00 PM EasternExtended Trading$1.66 +0.03 (+1.53%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CABA vs. AURA, CAPR, RNAC, INBX, ADCT, OLMA, AMRN, FHTX, RCKT, and OCGNShould you be buying Cabaletta Bio stock or one of its competitors? The main competitors of Cabaletta Bio include Aura Biosciences (AURA), Capricor Therapeutics (CAPR), Cartesian Therapeutics (RNAC), Inhibrx Biosciences (INBX), ADC Therapeutics (ADCT), Olema Pharmaceuticals (OLMA), Amarin (AMRN), Foghorn Therapeutics (FHTX), Rocket Pharmaceuticals (RCKT), and Ocugen (OCGN). These companies are all part of the "pharmaceutical products" industry. Cabaletta Bio vs. Its Competitors Aura Biosciences Capricor Therapeutics Cartesian Therapeutics Inhibrx Biosciences ADC Therapeutics Olema Pharmaceuticals Amarin Foghorn Therapeutics Rocket Pharmaceuticals Ocugen Cabaletta Bio (NASDAQ:CABA) and Aura Biosciences (NASDAQ:AURA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk. Do insiders and institutionals believe in CABA or AURA? 96.8% of Aura Biosciences shares are held by institutional investors. 11.3% of Cabaletta Bio shares are held by insiders. Comparatively, 5.4% of Aura Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts rate CABA or AURA? Cabaletta Bio currently has a consensus target price of $14.43, indicating a potential upside of 785.19%. Aura Biosciences has a consensus target price of $22.00, indicating a potential upside of 235.37%. Given Cabaletta Bio's higher possible upside, research analysts plainly believe Cabaletta Bio is more favorable than Aura Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cabaletta Bio 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00Aura Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 Which has more risk & volatility, CABA or AURA? Cabaletta Bio has a beta of 2.7, indicating that its stock price is 170% more volatile than the S&P 500. Comparatively, Aura Biosciences has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500. Does the media refer more to CABA or AURA? In the previous week, Cabaletta Bio had 5 more articles in the media than Aura Biosciences. MarketBeat recorded 6 mentions for Cabaletta Bio and 1 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 1.87 beat Cabaletta Bio's score of 0.58 indicating that Aura Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Cabaletta Bio Positive Aura Biosciences Very Positive Which has higher valuation & earnings, CABA or AURA? Aura Biosciences is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCabaletta BioN/AN/A-$115.86M-$2.54-0.64Aura BiosciencesN/AN/A-$86.92M-$1.90-3.45 Is CABA or AURA more profitable? Aura Biosciences' return on equity of -58.63% beat Cabaletta Bio's return on equity.Company Net Margins Return on Equity Return on Assets Cabaletta BioN/A -78.29% -65.68% Aura Biosciences N/A -58.63%-49.74% SummaryAura Biosciences beats Cabaletta Bio on 8 of the 12 factors compared between the two stocks. Get Cabaletta Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CABA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CABA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CABA vs. The Competition Export to ExcelMetricCabaletta BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$85.76M$2.90B$5.53B$9.30BDividend YieldN/A2.43%4.59%4.03%P/E RatioN/A20.2228.5619.60Price / SalesN/A182.78359.9473.66Price / CashN/A41.0524.7327.56Price / Book0.527.618.155.55Net Income-$115.86M-$55.11M$3.24B$257.73M7 Day Performance7.95%7.56%2.03%0.95%1 Month Performance-18.09%11.47%8.29%10.68%1 Year Performance-79.13%0.88%28.40%15.67% Cabaletta Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CABACabaletta Bio2.7859 of 5 stars$1.63-3.6%$14.43+785.2%-79.5%$85.76MN/A0.0050News CoverageAURAAura Biosciences2.5664 of 5 stars$6.79+6.1%$22.00+224.0%-21.1%$341.33MN/A-3.5750Positive NewsCAPRCapricor Therapeutics2.3856 of 5 stars$7.43-2.8%$22.56+203.7%+68.0%$339.27M$22.27M-5.23101Analyst ForecastGap DownRNACCartesian Therapeutics2.2406 of 5 stars$13.07-1.9%$40.00+206.2%-26.4%$339.04M$38.91M-0.2564INBXInhibrx Biosciences2.4763 of 5 stars$23.06+5.9%N/A+72.8%$333.92M$200K0.20166ADCTADC Therapeutics1.5392 of 5 stars$3.34+6.2%$7.75+131.8%-12.5%$331.66M$70.84M-2.31310OLMAOlema Pharmaceuticals2.4317 of 5 stars$4.85+4.2%$24.50+405.7%-60.7%$331.50MN/A-2.4170Positive NewsAMRNAmarin0.294 of 5 stars$15.98-5.6%$12.00-24.9%+3.1%$330.95M$228.61M-4.39360Positive NewsFHTXFoghorn Therapeutics1.9501 of 5 stars$5.90+9.2%$12.13+105.7%-4.7%$328.59M$22.60M-4.33120Positive NewsRCKTRocket Pharmaceuticals4.8395 of 5 stars$3.04+2.5%$18.60+512.9%-86.4%$324.11MN/A-1.15240OCGNOcugen1.3904 of 5 stars$1.11-3.1%$6.00+443.0%-41.0%$322.69M$4.05M-5.8280Positive News Related Companies and Tools Related Companies AURA Competitors CAPR Competitors RNAC Competitors INBX Competitors ADCT Competitors OLMA Competitors AMRN Competitors FHTX Competitors RCKT Competitors OCGN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CABA) was last updated on 7/15/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cabaletta Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cabaletta Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
